PL2755680T3 - Preparaty szczepionkowe w postaci cząstek - Google Patents

Preparaty szczepionkowe w postaci cząstek

Info

Publication number
PL2755680T3
PL2755680T3 PL12831495T PL12831495T PL2755680T3 PL 2755680 T3 PL2755680 T3 PL 2755680T3 PL 12831495 T PL12831495 T PL 12831495T PL 12831495 T PL12831495 T PL 12831495T PL 2755680 T3 PL2755680 T3 PL 2755680T3
Authority
PL
Poland
Prior art keywords
vaccine formulations
particulate vaccine
particulate
formulations
vaccine
Prior art date
Application number
PL12831495T
Other languages
English (en)
Polish (pl)
Inventor
Frank Bedu-Addo
Gregory Conn
Eric Jacobson
Carol MERCER
Kenya JOHNSON
Original Assignee
Pds Biotechnology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pds Biotechnology Corporation filed Critical Pds Biotechnology Corporation
Publication of PL2755680T3 publication Critical patent/PL2755680T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL12831495T 2011-09-12 2012-09-12 Preparaty szczepionkowe w postaci cząstek PL2755680T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161533512P 2011-09-12 2011-09-12
EP12831495.2A EP2755680B1 (en) 2011-09-12 2012-09-12 Particulate vaccine formulations
PCT/US2012/054786 WO2013039989A1 (en) 2011-09-12 2012-09-12 Particluate vaccine formulations

Publications (1)

Publication Number Publication Date
PL2755680T3 true PL2755680T3 (pl) 2019-03-29

Family

ID=47883670

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12831495T PL2755680T3 (pl) 2011-09-12 2012-09-12 Preparaty szczepionkowe w postaci cząstek

Country Status (8)

Country Link
US (2) US20150110823A1 (https=)
EP (1) EP2755680B1 (https=)
JP (2) JP6600459B2 (https=)
CN (2) CN104066444A (https=)
ES (1) ES2689799T3 (https=)
PL (1) PL2755680T3 (https=)
TW (1) TWI673062B (https=)
WO (1) WO2013039989A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2721366C (en) 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
CN104066444A (zh) * 2011-09-12 2014-09-24 Pds生物科技公司 微粒疫苗制剂
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
CN105101991A (zh) 2012-09-21 2015-11-25 Pds生物科技公司 改进的疫苗组合物和使用方法
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US20180221475A1 (en) * 2016-10-05 2018-08-09 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
SG11201902988UA (en) * 2016-10-05 2019-05-30 Pds Biotechnology Corp Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
CA3084957A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
CA3126544A1 (en) * 2019-01-12 2020-07-16 The Methodist Hospital Self-assembled peptide nanoparticle and use thereof
US20220409708A1 (en) * 2019-11-01 2022-12-29 Korea Advanced Institute Of Science And Technology Small lipid nanoparticles, and cancer vaccine including same
WO2023145749A1 (ja) * 2022-01-27 2023-08-03 一般財団法人阪大微生物病研究会 免疫賦活剤
EP4511061A1 (en) 2022-04-22 2025-02-26 Universitat Autònoma de Barcelona Immunogenic composition with protein micro- and nanoparticles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
AU6504596A (en) * 1995-07-21 1997-02-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2002060412A2 (en) * 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
US20050031587A1 (en) * 2002-10-04 2005-02-10 Yamanouchi Pharmaceutical Co., Ltd. Immune response induction method
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
CN1559607A (zh) * 2004-02-20 2005-01-05 �й�ũҵ��ѧ 一种核酸物质与蛋白质类组合物及其生产方法和在免疫调节中的应用
US7303881B2 (en) * 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
US20070059318A1 (en) * 2005-08-15 2007-03-15 Balu-Iyer Sathy V Lipid nano particulates containing antigens as cancer vaccines
CA2630220C (en) * 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
JP2007238559A (ja) * 2006-03-10 2007-09-20 Nagoya City Univ 未成熟樹状細胞活性化剤及びその使用
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2721366C (en) * 2008-04-17 2017-06-06 Elizabeth Ann Vasievich Stimulation of an immune response by enantiomers of cationic lipids
WO2011109294A1 (en) * 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
CN104066444A (zh) * 2011-09-12 2014-09-24 Pds生物科技公司 微粒疫苗制剂

Also Published As

Publication number Publication date
EP2755680A1 (en) 2014-07-23
EP2755680B1 (en) 2018-07-04
ES2689799T3 (es) 2018-11-15
US20190275145A1 (en) 2019-09-12
EP2755680A4 (en) 2015-04-15
TW201317001A (zh) 2013-05-01
US20150110823A1 (en) 2015-04-23
TWI673062B (zh) 2019-10-01
JP2018065821A (ja) 2018-04-26
CN110075292A (zh) 2019-08-02
JP6600459B2 (ja) 2019-10-30
WO2013039989A1 (en) 2013-03-21
CN104066444A (zh) 2014-09-24
JP2014527965A (ja) 2014-10-23

Similar Documents

Publication Publication Date Title
IL276234B (en) Antibody compositions
IL223206A0 (en) Vaccine formulations
PL2755680T3 (pl) Preparaty szczepionkowe w postaci cząstek
ZA201401012B (en) Parenteral novovirus vaccine formulations
IL232305A0 (en) pharmaceutical preparations
IL231043A (en) vaccine
GB201119999D0 (en) Vaccine
ZA201306245B (en) Combination vaccines
GB201120000D0 (en) Vaccine
GB201110278D0 (en) Formulations
GB201108256D0 (en) Vaccine
GB201121647D0 (en) Vaccine
GB201108984D0 (en) Vaccines
GB201108986D0 (en) Vaccines
GB201108982D0 (en) Vaccines
GB201104049D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201102795D0 (en) Formulations
GB201104048D0 (en) Formulations
GB201105360D0 (en) Formulations
GB201111578D0 (en) Pharmeutical formulations
GB201107626D0 (en) Formulations
GB201107627D0 (en) Formulations
GB201111013D0 (en) Formulations
GB201111577D0 (en) Pharmaceutical formulations